S936 Effectiveness and Safety of Upadacitinib for Crohn’s Disease: Real-World Data From a Tertiary Center

医学 不利影响 炎症性肠病 胃肠病学 类风湿性关节炎 阿达木单抗 内窥镜检查 克罗恩病 外科 疾病 内科学
作者
Cindy Traboulsi,Fares Ayoub,Alexa Silfen,Tina G. Rodriguez,David T. Rubin
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:116 (1): S445-S446 被引量:1
标识
DOI:10.14309/01.ajg.0000777276.68945.ff
摘要

Introduction: Upadacitinib (UPA) is a selective JAK-1 inhibitor approved for the treatment of rheumatoid arthritis (RA). Recently, the phase 2 CELEST trial showed that UPA induces endoscopic remission in Crohn’s disease (CD) patients at doses of 24mg twice daily and 24mg once daily. However, real world data are lacking. We describe the effectiveness and safety of UPA patients with CD at a tertiary center. Methods: We included patients with CD treated with UPA at _____ between 2019 and 2021. We retrospectively reviewed clinical, endoscopic, and histologic data to ascertain patient-reported subjective response and adverse event rates. Objective response was defined as any improvement in inflammatory markers, endoscopy, histology or imaging. Descriptive statistics and Wilcoxon signed rank test were performed. Results: Twelve patients with medically refractory disease (+/- joint involvement) were included: 9 women, 8 with ileo-colonic CD and 8 with fistulizing and/or penetrating CD. Most (67%) had perianal involvement and 83% had a history of bowel resection. All had prior exposure to biologics and 92% had extra-intestinal manifestations (Table 1). UPA was dosed at 15mg QD except in one patient who was started at 30mg QD and later transitioned to 15mg QD. Median treatment duration with UPA was 5.2 months (IQR 2.8–6.8) and 5 patients (42%) continued on therapy at the time of analysis. Subjectively, 25% reported improvement in their CD-related bowel symptoms and 33% in their joint pain. Four patients (33%) had objective evidence of response. There were no significant changes in routine hematologic and biochemical laboratory markers pre- and post-therapy (Figure 1). Adverse events resulting in treatment discontinuation were noted in 2 patients (1 fatigue and recurrent infections and 1 headache). Conclusion: In this cohort of medically-refractory patients with CD, treatment with UPA resulted in subjective and objective response in 25% and 33% of patients, respectively. To our knowledge, this is the first real-world report of UPA in patients with CD. Even at doses approved for RA that are considered lower than currently being studied for CD, UPA was associated with an overall favorable benefit/risk profile.Figure 1.: Percent Change in Median Lab Values Pre- and Post-Upadacitinib Therapy in Patients with CD.Table 1.: Demographic and Clinical Characteristics of Patients with CD Treated with Upadacitinib

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI65的应助被喜笑颜开采纳,获得10
1秒前
lym完成签到,获得积分10
2秒前
Zhuideal完成签到,获得积分10
4秒前
啊泽ovo完成签到,获得积分10
5秒前
梦游菌完成签到 ,获得积分10
6秒前
Xia完成签到 ,获得积分10
7秒前
缓慢仇天完成签到,获得积分10
7秒前
Wintlin完成签到,获得积分10
8秒前
沉默凌寒完成签到,获得积分10
9秒前
大白兔完成签到 ,获得积分10
13秒前
李钢完成签到,获得积分10
13秒前
清冷渊完成签到 ,获得积分10
13秒前
YiYi完成签到 ,获得积分10
15秒前
闹闹完成签到 ,获得积分10
15秒前
Keyuuu30完成签到,获得积分0
16秒前
海外寒完成签到 ,获得积分10
17秒前
等待鸽子完成签到,获得积分10
20秒前
zyx完成签到,获得积分10
20秒前
ttxxcdx完成签到 ,获得积分10
20秒前
hexing完成签到,获得积分10
21秒前
wanghao完成签到 ,获得积分10
21秒前
大惊完成签到,获得积分10
21秒前
李小浩完成签到 ,获得积分10
22秒前
dashi完成签到,获得积分10
24秒前
FanZao完成签到,获得积分10
26秒前
yang完成签到 ,获得积分10
26秒前
ljhwahaha完成签到,获得积分10
27秒前
桑稚完成签到 ,获得积分10
28秒前
Bo_0完成签到 ,获得积分10
28秒前
hkkogcu7449oi完成签到,获得积分10
28秒前
灵巧笑旋完成签到,获得积分10
30秒前
余又完成签到 ,获得积分10
31秒前
Bingo完成签到,获得积分10
31秒前
MrChew完成签到 ,获得积分10
32秒前
DrWho1985完成签到,获得积分10
33秒前
称心的菲鹰完成签到,获得积分10
33秒前
潜行者完成签到 ,获得积分10
34秒前
木香完成签到,获得积分10
34秒前
无辜丹翠完成签到 ,获得积分10
34秒前
儒雅曼岚完成签到,获得积分10
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185520
求助须知:如何正确求助?哪些是违规求助? 9574262
关于积分的说明 21834812
捐赠科研通 7783212
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481370